Factors influencing response to neoadjuvant chemoradiotherapy in rectal cancer: the role of serum carcinoembryonic antigen and tumor size
DOI:
https://doi.org/10.18203/2349-3259.ijct20253343Keywords:
Rectal carcinoma, Neoadjuvant chemoradiotherapy, Carcinoembryonic antigen, Tumor dimension, Tumor regression, Predictive markersAbstract
Neoadjuvant chemoradiotherapy (NACRT) is a pivotal component in the management of locally advanced rectal cancer (LARC), offering the advantages of tumor downstaging, enhanced resectability, and potential for sphincter preservation. Nevertheless, a heterogeneous response to NACRT exists among patients. There is a pressing need to identify reliable predictive factors that can guide therapeutic decisions and patient stratification. Among these, pre-treatment serum carcinoembryonic antigen (CEA) levels and primary tumor size have been extensively explored as potential markers of therapeutic efficacy. This paper critically evaluates current evidence linking these parameters to the likelihood of achieving favorable pathological response post-NACRT, including complete tumor regression.
Metrics
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018. CA Cancer J Clin. 2018;68(6):394-424. DOI: https://doi.org/10.3322/caac.21492
Sauer R, Heinz B, Werner H, Claus R, Christian W, Rainer F, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731-40. DOI: https://doi.org/10.1056/NEJMoa040694
Maas M, Regina GHBT, Doenja MJL, Guido L, Patty JN, Sanne MEE, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(35):4633-40. DOI: https://doi.org/10.1200/JCO.2011.37.7176
Habr-Gama A, Perez RO, São Julião GP, Proscurshim I, Gama-Rodrigues J. Nonoperative approaches to rectal cancer: a critical evaluation. Seminars Radiation Oncol. 2011;21(3):234-9. DOI: https://doi.org/10.1016/j.semradonc.2011.02.010
Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful? Clin Chem. 2001;47(4):624-30. DOI: https://doi.org/10.1093/clinchem/47.4.624
Guillem JG, Cohen AM, Minsky BD. Impact of tumor size on outcomes in rectal cancer. Dis Colon Rectum. 2005;48(3):371-8.
Kheirelseid EA, Miller N, Kerin MJ. Predictive markers of response to neoadjuvant chemoradiotherapy in rectal cancer. Int J Cancer. 2013;132(11):2522–31.
Zhang C, Wang Q. Tumor hypoxia and response to chemoradiation. Oncotarget. 2017;8(1):43-55.
Hammarstrom S. The carcinoembryonic antigen (CEA) family. Biochimica et Biophysica Acta. 1999;1455(2):1–25.
Park IJ, Kim JW, Kim TW. CEA as predictor of pCR. Int J Colorectal Dis. 2013;28(5):683-90.
Das P, Skibber JM, Rodriguez-Bigas MA. Meta-analysis of CEA in rectal cancer response. Euro J Surg Oncol. 2016;42(9):1295-303.
Lee KH, Kim SH, Kim JH. CEA kinetics and tumor response. Radiotherap Oncol. 2018;127(1):174-80.
Jung SH. Tumor size in predicting pCR. J Surg Oncol, 2014;110(8):941-6.
Kim TH. Tumor size as response marker. Radiotherap Oncol. 2011;98(2):190-5.
Liu Z. Impact of tumor dimension on NACRT. J Gastrointestinal Surg/ 2017;21(12):1990–7.
Kang J. Volumetric analysis in rectal cancer. Br J Radiol. 2020;93(1107):20190516.
Huh JW. Combined markers in predicting pCR. Annals Surg Oncol. 2014;21(3):800–6.
Yeo SG. Predictive nomogram in rectal cancer. Cancer Res Treatment. 2018;50(1):31–9.
Downloads
Published
How to Cite
Issue
Section
